Kuwanda kwehutano hwepfungwa kwakakwira zvakanyanya asi kuvandudzwa kwemishonga mitsva hakuna kuramba ichimhanya, zvichikonzera dambudziko mukurapa kwepfungwa. A novel innovation is psychedelic drug-assisted psychotherapy - kushandiswa kwakabvumidzwa nemishonga kweMDMA, psilocybin, uye LSD sechikamu chezvirongwa zvepamusoro zvepfungwa.
Chirevo kubva kuResearchAndMarkets chakataura kuti kusagadzikana idambudziko rehutano rinokurumidza pasi rese, kunyanya rakawedzera neCCIDID-19. Sekutsvagurudza kwakaitwa naHarvard, mutengo wekurapa wemamiriro ehutano hwepfungwa unofungidzirwa kukwira kusvika pamadhora matanhatu emadhora panosvika 6. Sekureva kwemuparidzi, musika wemishonga yepfungwa unotarisirwa kukura pamwero wakasimba we2030% CAGR panguva yekufanotaura uye kusvika pamutengo we $ 14.5 Mn muna 6330 kubva ku $ 2026 muna 3210 sezvo paine kudiwa kukuru kusingagone kurapwa kunotyaira kutorwa kwemishonga yepfungwa.
Chirevo chakaratidza ruzivo rwakakosha senge: Ketamine maziso CAGR ye16.0% pakati pezvigadzirwa zvese maererano nekukosha sezvo iine yakasimba yekiriniki miedzo yekiriniki mune dzakawanda zvirwere zvinoti. kuora mwoyo (MDD, TRD), bi-polar disorder, pfungwa yekuzviuraya, zvinodhaka nedoro, uye kushungurudzika kwevanhu; Zvigadzirwa zvine mavambo echisikigo zvinotarisirwa kuwana makumi mapfumbamwe eBPS maererano nekukosha kwemugove wemusika pakupera kwenguva yekufanotaura. Nekudaro, zvigadzirwa zvekugadzira zvichachengetedza nzvimbo yavo yemusika ine 90% mugove wemusika muna 85; Kushungurudzika kunofungidzirwa kubata yakakura chunk yechirwere chechiratidzo chikamu chine chikamu chinodarika makumi mana muzana chemusika muna 2026; uye Mishonga yeOral inofungidzirwa kupa zvinopfuura 40% kumusika wepasi rose wemishonga yepfungwa…”
ResearchAndMarkets akaenderera mberi achiti: “Kuwanda kwezvirwere zvepfungwa kwawedzera zvakanyanya asi kugadzirwa kwemishonga mitsva hakuna kuramba kuchikwira, zvichikonzera dambudziko mukurapa kwepfungwa. A novel innovation is psychedelic drug-assisted psychotherapy - kushandiswa kwakabvumidzwa nemishonga kweMDMA, psilocybin, uye LSD sechikamu chezvirongwa zvepamusoro zvepfungwa. North America inofungidzirwa kuti icharamba iri dunhu rakakura kwazvo mumusika wezvinodhaka wepsychedelic nekuda kwekuwanda kwemiedzo yekiriniki, kudyara kukuru, rutsigiro rwemitemo, uye kupararira kweruzhinji ruzivo. Iyo kondinendi inotora hafu yemari mumusika wepasi rose psychedelic mishonga uye inofanirwa kunge ichikosha madhora mazana matatu nemakumi mapfumbamwe neshanu pakupera kwenguva yekufanotaura. Kuvepo kwakasimba kwemakambani uye miedzo yekiriniki inoenderera mberi inotarisirwawo kuita zvakanaka pamusika wedunhu. "
Pasithea Therapeutics Inozivisa Zvirongwa Zvekuvhura Makiriniki Matsva Matatu muUK neMid-2022– Pasithea erapeutics Corp. (Pasithea” kana kuti “Company”), kambani inonyorwa yebiotechnology yakatarisana nekutsvagisa nekuwanikwa kwemishonga mitsva uye inoshanda yepfungwa netsinga. Makiriniki, Pasithea Clinics, yakawedzera kurapa kwayo uye iri kuronga kuvhura makiriniki matatu muLondon kurapa varwere vane hutano hwepfungwa. Iyo Kambani inotova nenzvimbo muMarylebone neKnightsbridge.
Makirinika aya, ayo achashandiswa nePasithea, achitsigirwa nehutungamiriri kubva kuZEN Healthcare, ari kutarisirwa kuvhurwa pakati pegore ra2022. Kiriniki yega yega ichapa mari inofungidzirwa kuti US$5 miriyoni pagore mumari.
Repeated transcranial magnetic stimulation ("rTMS") inzira yekurapa yehuropi-kusimudzira yakavakirwa pamusimboti weelectromagnetic induction. Kutanga kukudziridzwa muna 1985, rTMS yakadzidzwa semushonga wekuora mwoyo, psychosis, kuzvidya mwoyo, uye mamwe mamiriro ehutano hwepfungwa, uye yakaratidza kunyatsoshanda nemishonga isingagadzirisike kushushikana. Muna 2008, rTMS yakatenderwa kuti ishandiswe neFDA semushonga wekuora mwoyo kukuru kune varwere vasingadaviri kumushonga mumwe chete weanodzvinyirira. Chirongwa chemazuva ese chine marapiro mashanu pasvondo mukati memavhiki mana kusvika matanhatu.
ZVOKUBVA MUNYAYA INO:
- Or the “Company”), a novel biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders, today announced that its wholly owned subsidiary, Pasithea Clinics, has expanded its treatment offer and is planning to open three new clinics in London to treat patients suffering from mental health issues.
- 5% CAGR during the forecast period and reach a value of $6330 Mn in 2026 from $3210 in 2021 as there is a large unmet need for treatment driving the adoption of psychedelic drugs.
- In 2008, rTMS was approved for use by the FDA as a treatment for major depression for patients who do not respond to at least one antidepressant medication.
